EGFR and neoplasm: Accordingly, inhibition of the epidermal growth factor receptor (EGFR) via gefitinib in AOM/DSS mice led to decreased tumour burden, and this correlated with a reduction in intestinal epithelial cell Il33 expression which the authors attributed to for the pro-tumoral effect of EGFR signalling (85).